Mark DeLong - Feb 10, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Senior Vice President
Signature: /s/ David Watson, attorney-in-fact for Mark Delong
Stock symbol: APLS
Transactions as of: Feb 10, 2022
Transactions value $: -$12,770
Form type: 4
Date filed: 2/14/2022, 03:13 PM
Previous filing: Feb 1, 2022
Next filing: Apr 22, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Tax liability	-$12.8K	-271	-1.14%	$47.12	23.6K	Feb 10, 2022	Direct	F1
transaction	APLS	Common Stock	Award	$0	+4.9K	+20.78%	$0.00	28.5K	Feb 10, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$0	+6.95K		$0.00	6.95K	Feb 10, 2022	Common Stock	6.95K	$47.12	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents shares used to cover tax withholding on a Restricted Stock Unit release.
F2	This represents a restricted stock unit grant made on February 10, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.
F3	This represents a non-qualified stock option grant made on February 10, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.